Risk of hospital admission or emergency room visit for pneumonia in patients using respiratory inhalers: A case-crossover study

Respirology

Volumn 18, Issue 7, 2013, Pages 1116-1127

  Lee, Chang Hoon ^a,c   Jang, Eun Jin ^a   Hyun, Min Kyung ^a   Lee, Na Rae ^a,c   Kim, Kyungjoo ^b   Yim, Jae Joon ^a,c  

^a National Evidence Based Healthcare Collaborating Agency   (South Korea)

^b National Strategic Coordinating Center for Clinical Research   (South Korea)

^c Seoul National University   (South Korea)

Author keywords

asthma; chronic obstructive pulmonary disease; hospital admission; inhaled corticosteroid; pneumonia

Indexed keywords

BECLOMETASONE; BUDESONIDE; BUDESONIDE PLUS FORMOTEROL; CICLESONIDE; CORTICOSTEROID; FENOTEROL; FLUNISOLIDE; FLUTICASONE; FLUTICASONE PLUS SALMETEROL; FORMOTEROL; IPRATROPIUM BROMIDE; PROCATEROL; SALBUTAMOL; SALMETEROL; TERBUTALINE; TIOTROPIUM BROMIDE; TRIAMCINOLONE; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; ASTHMA; BRONCHIECTASIS; CHRONIC OBSTRUCTIVE LUNG DISEASE; CROSSOVER PROCEDURE; EMERGENCY WARD; FEMALE; HOSPITAL ADMISSION; HUMAN; INHALER; LUNG TUBERCULOSIS; MAJOR CLINICAL STUDY; MALE; PNEUMONIA; PRIORITY JOURNAL; RESPIRATORY TRACT DISEASE; RISK;

ASTHMA; CHRONIC OBSTRUCTIVE PULMONARY DISEASE; HOSPITAL ADMISSION; INHALED CORTICOSTEROID; PNEUMONIA;

ADRENAL CORTEX HORMONES; ADRENERGIC AGONISTS; ADULT; AGED; AGED, 80 AND OVER; CASE-CONTROL STUDIES; CROSS-OVER STUDIES; DATABASES, FACTUAL; EMERGENCY SERVICE, HOSPITAL; FEMALE; HOSPITALIZATION; HUMANS; MALE; MIDDLE AGED; NEBULIZERS AND VAPORIZERS; PNEUMONIA; RECEPTORS, ADRENERGIC, BETA-2; REPUBLIC OF KOREA; RISK FACTORS; TREATMENT OUTCOME;

EID: 84884884349     PISSN: 13237799     EISSN: 14401843     Source Type: Journal    
DOI: 10.1111/resp.12127     Document Type: Article

References (49)

1. Juniper EF, Kline PA, Vanzieleghem MA, et al. Effect of long-term treatment with an inhaled corticosteroid (budesonide) on airway hyperresponsiveness and clinical asthma in nonsteroid-dependent asthmatics. Am. Rev. Respir. Dis. 1990; 142: 832-836.
2. Pauwels RA, Lofdahl CG, Postma DS, et al. Effect of inhaled formoterol and budesonide on exacerbations of asthma. Formoterol and Corticosteroids Establishing Therapy (FACET) International Study Group. N. Engl. J. Med. 1997; 337: 1405-1411.
3. Suissa S, Ernst P, Benayoun S, et al. Low-dose inhaled corticosteroids and the prevention of death from asthma. N. Engl. J. Med. 2000; 343: 332-336.
4. Sin DD, McAlister FA, Man SF, et al. Contemporary management of chronic obstructive pulmonary disease: scientific review. JAMA 2003; 290: 2301-2312.
5. Wilt TJ, Niewoehner D, MacDonald R, et al. Management of stable chronic obstructive pulmonary disease: a systematic review for a clinical practice guideline. Ann. Intern. Med. 2007; 147: 639-653.
6. Johnson M,. Beta2-adrenoceptors: mechanisms of action of beta2-agonists. Paediatr. Respir. Rev. 2001; 2: 57-62.
7. Bateman ED, Boushey HA, Bousquet J, et al. Can guideline-defined asthma control be achieved? The Gaining Optimal Asthma ControL study. Am. J. Respir. Crit. Care Med. 2004; 170: 836-844.
8. O'Byrne PM, Barnes PJ, Rodriguez-Roisin R, et al. Low dose inhaled budesonide and formoterol in mild persistent asthma: the OPTIMA randomized trial. Am. J. Respir. Crit. Care Med. 2001; 164: 1392-1397.
9. Calverley PM, Anderson JA, Celli B, et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N. Engl. J. Med. 2007; 356: 775-789.
10. Celli BR, Thomas NE, Anderson JA, et al. Effect of pharmacotherapy on rate of decline of lung function in chronic obstructive pulmonary disease: results from the TORCH study. Am. J. Respir. Crit. Care Med. 2008; 178: 332-338.
11. Tashkin DP, Celli B, Senn S, et al. A 4-year trial of tiotropium in chronic obstructive pulmonary disease. N. Engl. J. Med. 2008; 359: 1543-1554.
12. Peters SP, Kunselman SJ, Icitovic N, et al. Tiotropium bromide step-up therapy for adults with uncontrolled asthma. N. Engl. J. Med. 2008; 363: 1715-1726.
13. Pasteur MC, Bilton D, Hill AT,. British Thoracic Society guideline for non-CF bronchiectasis. Thorax 2010; 65 (Suppl. 1): i1-58.
14. Martinez-Garcia MA, Perpina-Tordera M, Roman-Sanchez P, et al. Inhaled steroids improve quality of life in patients with steady-state bronchiectasis. Respir. Med. 2006; 100: 1623-1632.
15. Tsang KW, Tan KC, Ho PL, et al. Inhaled fluticasone in bronchiectasis: a 12 month study. Thorax 2005; 60: 239-243.
16. Singh S, Amin AV, Loke YK,. Long-term use of inhaled corticosteroids and the risk of pneumonia in chronic obstructive pulmonary disease: a meta-analysis. Arch. Intern. Med. 2009; 169: 219-229.
17. Suissa S, Kezouh A, Ernst P,. Inhaled corticosteroids and the risks of diabetes onset and progression. Am. J. Med. 2010; 123: 1001-1006.
18. Masoli M, Weatherall M, Holt S, et al. Inhaled fluticasone propionate and adrenal effects in adult asthma: systematic review and meta-analysis. Eur. Respir. J. 2006; 28: 960-967.
19. Richy F, Bousquet J, Ehrlich GE, et al. Inhaled corticosteroids effects on bone in asthmatic and COPD patients: a quantitative systematic review. Osteoporos. Int. 2003; 14: 179-190.
20. Weatherall M, James K, Clay J, et al. Dose-response relationship for risk of non-vertebral fracture with inhaled corticosteroids. Clin. Exp. Allergy 2008; 38: 1451-1458.
21. Weatherall M, Clay J, James K, et al. Dose-response relationship of inhaled corticosteroids and cataracts: a systematic review and meta-analysis. Respirology 2009; 14: 983-990.
22. Weatherall M, Wijesinghe M, Perrin K, et al. Meta-analysis of the risk of mortality with salmeterol and the effect of concomitant inhaled corticosteroid therapy. Thorax 2010; 65: 39-43.
23. Singh S, Loke YK, Furberg CD,. Inhaled anticholinergics and risk of major adverse cardiovascular events in patients with chronic obstructive pulmonary disease: a systematic review and meta-analysis. JAMA 2008; 300: 1439-1450.
24. Wedzicha JA, Calverley PM, Seemungal TA, et al. The prevention of chronic obstructive pulmonary disease exacerbations by salmeterol/fluticasone propionate or tiotropium bromide. Am. J. Respir. Crit. Care Med. 2008; 177: 19-26.
25. Drummond MB, Dasenbrook EC, Pitz MW, et al. Inhaled corticosteroids in patients with stable chronic obstructive pulmonary disease: a systematic review and meta-analysis. JAMA 2008; 300: 2407-2416.
26. Joo MJ, Au DH, Fitzgibbon ML, et al. Inhaled corticosteroids and risk of pneumonia in newly diagnosed COPD. Respir. Med. 2010; 104: 246-252.
27. Ernst P, Gonzalez AV, Brassard P, et al. Inhaled corticosteroid use in chronic obstructive pulmonary disease and the risk of hospitalization for pneumonia. Am. J. Respir. Crit. Care Med. 2007; 176: 162-166.
28. Mapel D, Schum M, Yood M, et al. Pneumonia among COPD patients using inhaled corticosteroids and long-acting bronchodilators. Prim. Care Respir. J. 2010; 19: 109-117.
29. Sin DD, Tashkin D, Zhang X, et al. Budesonide and the risk of pneumonia: a meta-analysis of individual patient data. Lancet 2009; 374: 712-719.
30. O'Byrne PM, Pedersen S, Carlsson LG, et al. Risks of pneumonia in patients with asthma taking inhaled corticosteroids. Am. J. Respir. Crit. Care Med. 2011; 183: 589-595.
31. Almirall J, Bolibar I, Serra-Prat M, et al. Inhaled drugs as risk factors for community-acquired pneumonia. Eur. Respir. J. 2010; 36: 1080-1087.
32. To M, To Y, Yamada H, et al. Influence of inhaled corticosteroids on community-acquired pneumonia in patients with bronchial asthma. Intern. Med. 2004; 43: 674-678.
33. Chen D, Restrepo MI, Fine MJ, et al. Observational study of inhaled corticosteroids on outcomes for COPD patients with pneumonia. Am. J. Respir. Crit. Care Med. 2011; 184: 312-316.
34. Malo de Molina R, Mortensen EM, Restrepo MI, et al. Inhaled corticosteroid use is associated with lower mortality for subjects with COPD and hospitalised with pneumonia. Eur. Respir. J. 2010; 36: 751-757.
35. Singanayagam A, Chalmers JD, Akram AR, et al. Impact of inhaled corticosteroid use on outcome in COPD patients admitted with pneumonia. Eur. Respir. J. 2011; 38: 36-41.
36. Kim DS,. Introduction: health of the health care system in Korea. Soc. Work Public Health 2010; 25: 127-141.
37. Jang MJ, Bang SM, Oh D,. Incidence of venous thromboembolism in Korea: from the Health Insurance Review and Assessment Service database. J. Thromb. Haemost. 2011; 9: 85-91.
38. Kim NH, Kim HJ, Cheong HK, et al. Prevalence of multiple sclerosis in Korea. Neurology 2010; 75: 1432-1438.
39. Kang HY, Yang KH, Kim YN, et al. Incidence and mortality of hip fracture among the elderly population in South Korea: a population-based study using the national health insurance claims data. BMC Public Health 2010; 10: 230.
40. Lee JH, Park YS, Choi JS,. The epidemiology of appendicitis and appendectomy in South Korea: national registry data. J. Epidemiol. 2010; 20: 97-105.
41. Kim HA, Kim S, Seo YI, et al. The epidemiology of total knee replacement in South Korea: national registry data. Rheumatology (Oxford) 2008; 47: 88-91.
42. Berger ML, Mamdani M, Atkins D, et al. Good research practices for comparative effectiveness research: defining, reporting and interpreting nonrandomized studies of treatment effects using secondary data sources: the ISPOR Good Research Practices for Retrospective Database Analysis Task Force Report-Part I. Value Health 2009; 12: 1044-1052.
43. Horwitz RI, Feinstein AR,. The problem of 'protopathic bias' in case-control studies. Am. J. Med. 1980; 68: 255-258.
44. Metlay JP, Kapoor WN, Fine MJ,. Does this patient have community-acquired pneumonia? Diagnosing pneumonia by history and physical examination. JAMA 1997; 278: 1440-1445.
45. Calverley PM, Spencer S, Willits L, et al. Withdrawal from treatment as an outcome in the ISOLDE study of COPD. Chest 2003; 124: 1350-1356.
46. Lemanske RF Jr, Mauger DT, Sorkness CA, et al. Step-up therapy for children with uncontrolled asthma receiving inhaled corticosteroids. N. Engl. J. Med. 2010; 362: 975-985.
47. Lieberman D, Lieberman D, Gelfer Y, et al. Pneumonic vs nonpneumonic acute exacerbations of COPD. Chest 2002; 122: 1264-1270.
48. Mortimer KJ, Tattersfield AE, Tang Y, et al. Plasma concentrations of fluticasone propionate and budesonide following inhalation: effect of induced bronchoconstriction. Br. J. Clin. Pharmacol. 2007; 64: 439-444.
49. Halpin DM, Gray J, Edwards SJ, et al. Budesonide/formoterol vs. salmeterol/fluticasone in COPD: a systematic review and adjusted indirect comparison of pneumonia in randomised controlled trials. Int. J. Clin. Pract. 2008; 65: 764-774.